CA2290509A1 - 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors - Google Patents

2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors Download PDF

Info

Publication number
CA2290509A1
CA2290509A1 CA002290509A CA2290509A CA2290509A1 CA 2290509 A1 CA2290509 A1 CA 2290509A1 CA 002290509 A CA002290509 A CA 002290509A CA 2290509 A CA2290509 A CA 2290509A CA 2290509 A1 CA2290509 A1 CA 2290509A1
Authority
CA
Canada
Prior art keywords
methyl
iodo
phenylamino
benzamide
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002290509A
Other languages
French (fr)
Inventor
Stephen Douglas Barrett
Alexander James Bridges
Donna Reynolds Cody
Annette Marian Doherty
David Thomas Dudley
Alan Robert Saltiel
Mel Conrad Schroeder
Haile Tecle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2290509A1 publication Critical patent/CA2290509A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/68—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
    • C07C229/58—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position having the nitrogen atom of at least one of the amino groups further bound to a carbon atom of a six-membered aromatic ring, e.g. N-phenyl-anthranilic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/36—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C07C243/38—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/44—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/28—Nitrogen atoms
    • C07D295/32—Nitrogen atoms acylated with carboxylic or carbonic acids, or their nitrogen or sulfur analogues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Phenylamino benzoic acid, benzamides, and benzyl alcohol derivatives of formula (I) where R1, R2, R3, R4, R5, and R6 are hydrogen or substituent groups such as alkyl, and where R7 is hydrogen or an organic radical, and Z is COOR7, tetrazolyl, CONR6R7, or CH2OR7, are potent inhibitors of MEK and, as such, are effective in treating cancer and other proliferative diseases such as inflammation, psoriasis and restenosis, as well as stroke, heart failure, and immunodeficiency disorders.

Description

2-(4-BROMO OR 4-IODO PHENYLAM1N0) BENZOIC ACID DERIVATIVES
AND THEIR USE AS MEK INHIBITORS
FIELD OF THE INVENTION
This invention provides benzoic acid and amide derivatives of anthranilic acids which inhibit certain dual specificity kinase enzymes involved in proliferative diseases such as cancer and restenosis.
BACKGROUND OF THE INVENTION
Proliferative diseases are caused by a defect in the intracellular signaling system, or the signal transduction mechanism of certain proteins. Cancer, for example, is commonly caused by a series of defects in these signaling proteins, resulting from a change either in their intrinsic activity or in their cellular concentrations. The cell may produce a growth factor that binds to its own receptors, resulting in an autocrine loop, which continually stimulates proliferation. Mutations or overexpression of intracellular signaling proteins can lead to spurious mitogenic signals within the cell. Some of the most common mutations occur in genes encoding the protein known as Ras, which is a G-protein that is activated when bound to GTP, and inactivated when bound to GDP.
The above mentioned growth factor receptors, and many other mitogenic receptors, when activated, lead to Ras being converted from the GDP-bound state to the GTP-bound state. This signal is an absolute prerequisite for proliferation in most cell types. Defects in this signaling system, especially in the deactivation of the Ras.GTP complex, are common in cancers, and lead to the signaling cascade below Ras being chronically activated.
Activated Ras leads in turn to the activation of a cascade of serine/threonine kinases. One of the groups of kinases known to require an active Ras.GTP for its own activation is the Raf family. These in turn activate MEK, (eg, MEK1 and MEK2) which then activates MAP kinase. Activation of MAP kinase by mitogens appears to be essential for proliferation, and constitutive activation of this kinase is sufficient to induce cellular transformation. Blockade of downstream Ras signaling, for example by use of a dominant negative Raf 1 protein, can completely inhibit mitogenesis, whether induced from cell surface receptors or from oncogenic Ras mutants. Although Ras is not itself a protein kinase, it participates in the activation of Raf and other kinases, most likely through a phosphorylation mechanism. Once activated, Raf and other kinases phosphorylate MEK on two closely adjacent serine residues, S21 g and 5222 in the case of MEK-1, which are the prerequisite for activation of MEK as a kinase. MEK in turn phosphorylates MAP kinase on both a tyrosine, Y1 g5, and a threonine residue, T1 g3, separated by a single amino acid. This double phosphorylation activates MAP kinase at least 100-fold, and it can now catalyze the phosphorylation of a large number of proteins, including several transcription factors and other kinases. Many of these MAP kinase phosphorylations are mitogenically activating for the target protein, whether it be another kinase, a transcription factor, or other cellular protein. MEK is also activated by several kinases other than Raf 1, including MEKK, and itself appears to be a signal integrating kinase. As far as is currently known, MEK is highly specific for the phosphorylation of MAP kinase. In fact, no substrate for MEK other than MAP
kinase has been demonstrated to date, and MEK does not phosphorylate peptides based on the MAP kinase phosphorylation sequence, or even phosphorylate denatured MAP kinase. MEK also appears to associate strongly with MAP kinase prior to phosphorylating it, suggesting that phosphorylation of MAP kinase by MEK may require a prior strong interaction between the two proteins. Both this requirement and the unusual specificity of MEK are suggestive that it may have enough difference in its mechanism of action to other protein kinases that selective inhibitors of MEK, possibly operating through allosteric mechanisms rather than through the usual blockade of the ATP binding site, may be found.
This invention provides compounds which are highly specific inhibitors of the kinase activity of MEK. Both in enzyme assays and whole cells, the compounds inhibit the phosphorylation of MAP kinase by MEK, thus preventing the activation of MAP kinase in cells in which the Ras cascade has been activated.
The results of this enzyme inhibition include a reversal of transformed phenotype of some cell types, as measured both by the ability of the transformed cells to grow in an anchorage-independent manner and by the ability of some transformed cell lines to proliferate independently of external mitogens.
- The compounds provided by this invention are 2-(phenylamino) benzoic acid, tetrazole, ester, amide, and benzyl alcohol derivatives, in which the phenyl ring is substituted at the 4-position with bromo or iodo. United States Patent No. 5,155,110 discloses a wide variety of fenamic acid derivatives, including certain 2-(phenylamino) benzoic acid derivatives, as anti-inflammatory agents.
The reference fails to describe the compounds of this invention or their kinase inhibitory activity.
SUMMARY OF THE INVENTION
This invention provides 4-bromo and 4-iodo phenylamino benzoic acid derivatives which are selective MEK kinase inhibitors and as such are useful for treating proIiferative diseases such as cancer, psoriasis, and restenosis. The compounds are defined by Formula I
R Z
R1 ( 2 N
/ ~ RS I
Br or I

wherein:
R1 is hydrogen, hydroxy, C1-Cg alkyl, C1-Cg alkoxy, halo, trifluoromethyl, or CN;
R2 is hydrogen;
R3, R4, and RS independently are hydrogen, hydroxy, halo, trifluoromethyl, - C1-Cg alkyl, C1-Cg alkoxy, nitro, CN, or -(O or NH)m -(CH2)n-R9, where R9 is hydrogen, hydroxy, C02H, or NR1 OR11 n is 0-4;

_d_ mis0orl;
RI O and RI I independently are hydrogen or C1-Cg alkyl, or taken together with the nitrogen to which they are attached, can complete a 3-10 member cyclic ring optionally containing one, two, or three additional heteroatoms selected from O, S, NH, or N-C1-Cg alkyl;
Z is COORS, tetrazolyl, CONR6R~, CONHNRI ORI 1 ~ or CH20R~;
R6 and R~ independently are hydrogen, CI-Cg alkyl, C2-Cg aIkenyl, O
C2-Cg alkynyl, C-CI-Cg alkyl, aryl, heteroaryl, C3-C10 cycloalkyl, or C3-C l 0 (cycloalkyl optionally containing one, two, or three heteroatoms selected from O, S, NH, or N alkyl); or R6 and R~ together with the nitrogen to which they are attached complete a 3-I0 member cyclic ring optionally containing 1, 2, or 3 additional heteroatoms selected from O, S, NH, or N alkyl;
and wherein any of the foregoing alkyl, alkenyl, and alkynyl groups can be unsubstituted or substituted by halo, hydroxy, alkoxy, amino, alkylamino, dialkylamino, cycloalkyl, aryl, aryloxy, heteroaryl, or heteroaryloxy, and the pharmaceutically acceptable salts thereof.
Preferred compounds have Formula II
O
I I
C-O-R~

N ~ II
I RS
Br or I

where R1, R3, R4, R5, R6, and R~ are as defined above. Especially preferred are compounds wherein R1 is methyl or halo, and R3, R4, and RS are halo such as fluoro or bromo.

The compounds of Formula II are carboxylic acids when R~ is hydrogen, and are esters when R~ is other than hydrogen. Compounds which are analogous to the acids in physical and biological properties are tetrazolyl derivatives of Formula IIa N-N
/
N ~ NCR

N
/ I R-5 or Br or I

IIa ~R9 N-N
//
N ,N

N
/ I RS
Br or I

Another preferred group of compounds are amides Formula III
O
I I
R C - NR6R~

N
III
/ /
Br or I
v R3 wR5 and hydrazides of Formula IIIa O
I l R C -NHNR1 ~Rl 1 N \
IIIa Br or I
v R3 wR5 The benzyl alcohols of the invention have Formula IV
R H~OR~

N
~ I RS IV
Br or I

The most preferred compounds are those wherein R1 is methyl, R3 is hydrogen or halo such as fluoro, R4 is halo such as fluoro, and R5 is hydrogen or halo such as fluoro, bromo, or chloro. Representative compounds have the formulas H H
\ \ N \
Br or I Br or I F
F F

H H
\ \ N \
Br or I / F / Bi Br or I / F ~ F
F F F

This invention also provides pharmaceutical formulations comprising a compound of Formula I together with a pharmaceutically acceptable excipient, diluent, or carrier. Preferred formulations include any of the foregoing preferred compounds together with an excipient, diluent, or carrier.
The compounds of Formula I are potent and selective inhibitors of MEK1 and MEK2 kinase enzymes. They are, therefore, useful to treat subjects suffering from cancer, stroke, diabetes, Alzheimer's disease, cystic fibrosis, viral disease, heart failure, and proliferative diseases such as psoriasis, restenosis, autoimmune disease, and atherosclerosis. The compounds are especially well suited to treat cancers such as breast cancer, colon cancer, prostate cancer, skin cancer, and pancreatic cancer. They are particularly well-suited for use in conjunction with conventional radiation therapy. The compounds are also immunomodulatory agents and can be used to treat degenerative diseases where change in MEK activation leads to pathologies such as hepatomegaly and cardiomegaly. The invention provides a method of inhibiting MEK enzymes and the foregoing diseases by administering to a subject an effective amount of a compound of Formula I.
DETAILED DESCRIPTION OF THE INVENTION
As used herein, the term "aryl" means a cyclic, bicyclic, or tricyclic aromatic ring moiety having from five to twelve carbon atoms. Examples of typical aryl groups include phenyl, naphthyl, and fluorenyl. The aryl may be substituted by one, two, or three groups selected from fluoro, chloro, bromo, iodo, alkyl, hydroxy, alkoxy, nitro, amino, alkylamino, or dialkylamino. Typical substituted aryl groups include 3-fluorophenyl, 3,5-dimethoxyphenyl, 4-nitronaphthyl, 2-methyl-4-chloro-7-aminofluorenyl, and the like.
The term "aryloxy" means an aryl group bonded through an oxygen atom, for example phenoxy, 3-bromophenoxy, naphthyloxy, and 4-methyl-1-fluorenyloxy.
"Heteroaryl" means a cyclic, bicyclic, or tricyclic aromatic ring moiety having from four to eleven carbon atoms and one, two, or three heteroatoms _g_ selected from O, S, or N. Examples include furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl, oxazolyl, xanthenyl, pyronyl, indolyl, pyrimidyl, naphthyridyl, pyridyl, benzinnidazolyi, and triazinyl. The heteroaryl groups can be unsubstituted or substituted by one, two, or three groups selected from fluoro, chloro, bromo, iodo, alkyl, hydroxy, alkoxy, nitro, amino, alkylamino, or dialkylamino. Examples of substituted heteroaryl groups include chloropyranyl, methylthienyl, fluoropyridyl, amino-1,4-benzisoxazinyl, nitroisoquinolinyl, and hydroxyindolyl.
The heteroaryl groups can be bonded through oxygen to make heteroaryloxy groups, for example thienyloxy, isothiazolyloxy, benzofuranyloxy, pyridyloxy, and 4-methylisoquinolinyloxy.
The term "C 1-Cg alkyl" means straight and branched chain aliphatic groups having from one to eight carbon atoms, preferably one to four. Typical C1-Cg alkyl groups include methyl, ethyl, isopropyl, tert.-butyl, 2,3-dimethylhexyl, and l,l-dimethylpentyl. The alkyl groups can be unsubstituted or substituted by halo, hydroxy, alkoxy, amino, alkylamino, dialkylamino, cycloalkyl, aryl, aryloxy, heteroaryl, or heteroaryloxy, as those terms are defined herein. Typical substituted alkyl groups include chloromethyl, 3-hydroxypropyl, 2-dimethylaminobutyl, and 2-(hydroxymethylamino)ethyl. Examples of aryl and aryloxy substituted alkyl groups include phenylmethyl, 2-phenylethyl, 3-chlarophenylmethyl, 1,1-dimethyl-3-(2-nitrophenoxy)butyl, and 3,4,5-trifluoronaphthylmethyl. Examples of alkyl groups substituted by a heteroaryl or heteroaryloxy group include thienylmethyl, 2-furylethyl, 6-furyloxyoctyl, 4-methylquinolyloxymethyl, and 6-isothiazolylhexyl.
CycloaIkyl substituted alkyl groups include cyclopropylmethyl, 2-cyclohexyethyl, piperidyl-2-methyl, 2-(piperidin-1-yl)-ethyl, 3-(morpholin-4-yl)propyl.
"C2-Cg Alkenyl" means a straight or branched carbon chain having one or more double bonds. Examples include but-2-enyi, 2-methyl-prop-2-enyl, 1,1-dimethyl-hex-4-enyl, 3-ethyl-4-methyl-pent-2-enyl, and 3-isopropyl-pent-4-enyl. The alkenyl groups can be substituted with halo, hydroxy, alkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy, heteroaryl, or heteroyloxy, for example 2-bromoethenyl, 3-hydroxy-2-butenyl, 1-aminoethenyl, 3-phenylprop-2-enyl, 6-thienyl-hex-2-enyl, 2-furyloxy-but-2-enyl, and 4-naphthyloxy-hex-2-enyl.
"C2-Cg Alkynyl" means a straight or branched carbon chain having from two to eight carbon atoms and at least one triple bond. Typical alkynyl groups include prop-2-ynyl, 2-methyl-hex-5-ynyl, 3,4-dimethyl-hex-5-ynyl, and 2-ethyl-but-3-ynyl. The alkynyl groups can be substituted as the alkyl and alkenyl groups, for example, by aryl, aryloxy, heteroaryl, or heteroaryloxy, for example 4-(2-fluorophenyl)-but-3-ynyl, 3-meth 1-5-thienylpent-4-ynyl, 3-phenoxy-hex-4-ynyl, and 2-furyloxy-3-methyl-hex-4-ynyl.
The alkenyl and alkynyl groups can have one or more double bonds or triple bonds, respectively, or a combination of double and triple bonds. For example, typical groups having both double and triple bonds include hex-2-en-4-ynyl, 3-methyl-5-phenylpent-2-en-4-ynyl, and 3-thienyloxy-hex-3-en-5-ynyl.
The term "C3-C 10 cycloalkyl" means a nonaromatic ring or fused rings containing from three to ten carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopenyl, cyclooctyl, bicycloheptyl, adamantyl, and cyclohexyl.
The ring can optionally contain one, two, or three heteroatoms selected from O, S, or NR9. Such groups include tetrahydrofuryl, tetrahydropyrrolyl, octahydrobenzofuranyl, morpholinyl, piperazinyl, pyrrolidinyl, piperidinyl, octahydroindolyl, and octahydrobenzothiofuranyl. The cycloalkyl groups can be substituted with the same substituents as an alkyl and alkenyl groups, for example, halo, hydroxy, aryl, and heteroaryloxy. Examples include 3-hydroxycyclohexyl, 2-aminocyclopropyl, 2-phenylpyrrolidinyl, and 3-thienylmorpholine-1-yl.
R6 and R~ can be taken together with the nitrogen to which they are attached to complete a cyclic ring having from 3 to 10 members, which may contain 1, 2, or 3 additional heteroatoms selected from O, S, NH, or N
alkyl.
Examples of such cyclic rings include piperazinyl, piperidyl, pyrrolidinyl, morpholino, N-methylpiperazinyl, aziridynyl, and the like. Such rings can be substituted with halo, hydroxy, alkyl, alkoxy, amino, alkyl, and dialkylamino, aryl, aryloxy, heteroaryl, and heteroaryloxy. Typical examples include 3-hydroxy-pyrrolidinyl, 2-fluoro-piperindyl, 4-(2-hydroxyethyl)-piperidinyl, and 3-thienylmorpholino.

The 2-(4-bromo and 4-iodo phenylamino)-benzoic acid derivatives of Formula I can be prepared from commercially available starting materials utilizing synthetic methodologies well-known to those skilled in organic chemistry. A
typical synthesis is carried out by reacting a 4-bromo or 4-iodo aniline with a benzoic acid having a leaving group at the 2-position to give a 2-(phenylamino)-benzoic acid. This process is depicted in Scheme 1.
Scheme 1 O
R II

\ NH L \
+ ( RS
Br or 1 base O
I I
R ~ 2 C-OH
I
\ N \

Br or I v v\

where L is a leaving group, for example halo such as fluoro.
The reaction of aniline and the benzoic acid derivative generally is accomplished by mixing the benzoic acid with an equimolar quantity or excess of the aniline in an unreactive organic solvent such as tetrahydrofuran or toluene, in the presence of a base such as lithium diisopropylamide, n-butyl lithium, sodium hydride, triethylamine, and Hunig's base. The reaction generally is carried out at a temperature of about -78°C to about 100°C, and normally is complete within about 2 hours to about 4 days. The product can be isolated by removing the solvent, for example by evaporation under reduced pressure, and further purified, if desired, by standard methods such as chromatography, crystallization, or distillation.
The 2-(phenylamino)-benzoic acid (eg, Formula I, where R~ is hydrogen) can be reacted with an organic or inorganic base such as pyridine, triethylamine, calcium carbonate, or sodium hydroxide to produce a pharmaceutically acceptable salt. The free acids can also be reacted with an alcohol of the formula FIOR~ (where R~ is other than hydrogen, for example methyl) to produce the corresponding ester. Reaction of the benzoic acid with an alcohol can be carried out in the presence of a coupling agent. Typical coupling reagents include 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ), 1,3-dicyclohexylcarbodiimide (DCC}, bromo-tris(pyrrolidino)-phosphonium hexafluorophosphate (PyBrOP), and (benzotriazolyloxy) tripyrrolidino phosphonium hexafluorophosphate (PyBOP). The phenylamino benzoic acid and alcohol derivative normally are mixed in approximately equimolar quantities in an unreactive organic solvent such as dichloromethane, tetrahydrofuran, chloroform, or xylene, and an equimolar quantity of the coupling reagent is added. A base such as triethylamine or diisopropylethylamine can be added to act as an acid scavenger if desired. The coupling reaction generally is complete after about 10 minutes to 2 hours, and the product is readily isolated by removing the reaction solvent, for instance by evaporation under reduced pressure, and purifying the product by standard methods such as chromatography or crystallizations from solvents such as acetone, diethyl ether, or ethanol.
The benzamides of the invention, Formula I where Z is CONR6R~, are readily prepared by reacting the foregoing benzoic acids with an amine of the formula HNR6R~. The reaction is carried out by reacting approximately equimolar quantities of the benzoic acid and amine in an unreactive organic solvent in the presence of a coupling reagent. Typical solvents are chloroform, dichloromethane, tetrahydrofuran, benzene, toluene, and xylene. Typical coupling reagents include DCC, EEDQ, PyBrOP, and PyBOP. The reaction is generally complete after about 10 minutes to about 2 hours when carried out at a temperature of about 0°C to about 60°C. The product amide is readily isolated by removing the reaction solvent, for instance by evaporation, and further purification can be accomplished by normal methods such as chromatography, crystallization, or distillation. The hydrazides (z = CONHNRIpRI 1 ) are similarly prepared by coupling a benzoic acid with a hydrazine of the formula H2HNR1 pRl 1-The benzyl alcohols of the invention, compounds of Formula I where Z is CH20R6 and R6 is hydrogen, are readily prepared by reduction of the corresponding benzoic acid according to the following scheme ~2 C - OH ~2 H20H
Rl N RI
reducing ~ ~ N
went Br or I
Br or I

Typical reducing agents commonly employed include borane in tetrahydrofuran.
The reduction normally is carried out in an unreactive organic solvent such as tetrahydrofuran, and generally is complete within about 2 hours to about 24 hours when conducted at a temperature of about 0°C to about 40°C.
The following detailed examples illustrate specific compounds provided by this invention.

4-Fluoro-2-(4-iodo-2-methylphenylamino~benzoic acid To a stirring solution comprised of 3.16 g (0.0133 mol) of 2-amino-5-iodotoluene in 5 mL of tetrahydrofuran at -78°C was added 10 mL
(0.020 mol) of a 2.0 M lithium diisopropylamide in tetrahydrofuran/heptane/ethenylbenzene (Aldrich) solution. The resulting green suspension was stirred vigorously for 15 minutes, after which time a solution of 1.00 g (0.00632 mol) of 2,4-difluorobenzoic acid in 10 mL of tetrahydrofuran was added. The reaction temperature was allowed to increase slowly to room temperature, at which temperature it was stirred for 2 days. The reaction mixture was concentrated.

Aqueous HCl (10%) was added to the concentrate, and the solution was extracted with dichloromethane. The organic phase was dried (MgS04) and then boiled over a steambath to low volume and cooled to room temperature. The off white fibers were collected by vacuum filtration, rinsed with hexanes, and vacuum-oven dried. (76°C; ca. 10 mm of Hg) to afford I .10 g (47%) of the desired material;
mp 224-229.5°C;
1 H NMR (400 MHz; DMSO): A 9.72 (s, 1 H), 7.97 (dd, 1 H, J = 7.0, 8.7 Hz), 7:70 (d, 1 H, J = 1.5 Hz), 7.5 7 (dd, 1 H, J = 8.4, 1.9 Hz), 7.17 (d, 1 H, J =
8.2 Hz), 6.61-6.53 (m, 2H), 2.18 (s, 3H);
13C NMR (100 MHz; DMSO): A 169.87, 167.60, 165.12, 150.17, 150.05, 139.83, 138.49, 136.07, 135.31, 135.20, 135.07, 125.60, 109.32, 105.09, 104.87, 99.72, 99.46, 89.43, 17.52;
19F NMR (376 MHz; DMSO): 8 -104.00 to -104.07 (m);
IR (KBr) 1670 (C = O stretch) cm' 1;
MS (CI) M+1 = 372.
Analysis calculated for C 14H 11 F~02 C, 45.31; H, 2.99; N, 3.77.
Found: C, 45.21; H, 2.77; N, 3.64.

By following the general procedure of Example 1, the following benzoic acids and salts were prepared:

~;xample Compound MP ~C
No.
2 3,4,5-Trifluoro-2-(4-iodo-2-methyl-phenylamino)- 206-210 benzoic acid 3 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic 240.5-244.5 acid 4 S-Bromo-3,4-difluoro-2-(4-iodo-2-methyl- 259.5-262 phenylamino)-benzoic acid 5-Chloro-2-(2-chloro-4-iodo-phenylamino)-benzoic acid 255-260 6 S-Chloro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid 234-238 Example Compound MP ~C

No.
7 Sodium S-Chloro-2-(4-iodo-2-methyl-phenylamino)-310-320 DEC

benzoate 8 S-Bromo-2-(4-iodo-2-methyl-phenylamino)-benzoic239.5-240 acid 9 2-(2-Chloro-4-iodo-phenylamino)-S-nitro-benzoic289-293 acid 4-Fluoro-2-(3-fluoro-4-iodo-2-methyl-phenylamino)-233-23S

benzoic acid 11 2-(4-Iodo-2-methyl-phenylamino)-S-nitro-benzoic264-267 acid 12 2-(2-Fluoro-4-iodo-phenylamino)-S-nitro-benzoic2S6-2S8 acid 13 2-(4-Bromo-2-methyl-phenylamino)-4-fluoro-benzoic218.5-acid 14 2-(2-Bromo-4-iodo-phenylarnino)-S-nitro-benzoic28S-288 acid DEC

1 S 2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-230-234 benzoic acid 16 3-Fluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic218-221 acid 17 3,4-Difluoro-2-(4-iodo-2-methoxy-phenylamino)-230-233 benzoic acid 18 4-Chloro-2-(4-iodo-2-methyl-phenylamino)-benzoic24S-2SS
acid DEC

19 2-(4-Iodo-2-methyl-phenylamino)-benzoic218-223 acid S-Fluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic243-46 acid 21 S-Iodo-2-(4-iodo-2-methyl-phenylamino)-benzoic241-24S
acid 22 2,3,5-Trifluoro-4-(4-iodo-2-methyl-phenylamino)-218-222 benzoic acid 23 4-Fluoro-2-(3-chloro-4-iodo-2-methyl-phenylamino)-248-2S2.S

benzoic acid 24 2-(4-Iodo-phenylamino)-S-methoxy-benzoic208-211 acid 2S 3-Chloro-2-(2-chloro-4-iodo-phenylamino)-benzoic232-233 acid 26 2-Fluoro-6-(4-iodo-2-methyl-phenylamino)-benzoic179-182 acid 27 4-Fluoro2-(2,3-dimethyl-4-iodo-2-methyl-phenylamino)-2S8-benzoic acid 28 S-Methyl-2-(4-iodo-2-methyl-phenylamino)-benzoic209.5-211 acid 29 2-Chloro-6-(4-iodo-2-methyl-phenylamino)-benzoic171-17S
acid 2-{4-Iodo-2-methyl-phenylamino)-4-nitro-benzoic2S1-263 acid 5-Chloro-N-(2-hydroxyethyl)-2-(4-iodo-2-methyl~henylamino)-benzamide To a stirring solution comprised of 0.1020 g (0.2632 mmol) of 5-chloro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid, 0.1 mL (1.7 mmol) of ethanolamine, and 0.05 mL (0.29 mmol) of diisopropylethylamine in 5 mL of a 1:1 (v/v) tetrahydrofuran-dichloromethane solution was added 0.15 g (0.29 mmol) of solid PyBOP powder directly. The reaction mixture was stirred at room temperature overnight. The solvent was removed in vacuo. The crude residue was partitioned between ether (SO mL) and 10% aqueous hydrochloric acid (50 mL).
T'he organic phase was washed with 10% aqueous sodium hydroxide (50 mL), dried (MgS04) and concentrated in vacuo to afford a yellow-brown oil which was crystallized from hexanes-ether to afford 0.0831 g (73%) of a green-yellow powder; mp 120-121 °C;
1 H NMR (400 MHz; CDC13): 8 9.11 (s, 1 H), 7.56 (d, 1 H, J = 1.4 Hz), 1 S 7.46-7.41 (m, 2H), 7.20 (dd, 1 H, J = 8.9, 2.4 Hz), 7.00 (t, 2H, J = 9.6 Hz), 6.55 (broad t, 1H), 3.86 (t, 2H, J = 5.0 Hz), 3.61 (dd, 2H, J = 10.1, 5.5 Hz), 2.23 (s, 3H), 1.56 (broad s, 1H);
IR (KBr) 3297 (O-H stretch), 1627 (C = O stretch) cm-1;
MS (CI) M+1 = 431.
Analysis calculated for C 16H 16C1~202:
C, 44.62; H, 3.74; N, 6.50.
Found: C, 44.63; H, 3.67; N, 6.30.

By following the general procedure of Example 31, the following benzamides were prepared by reacting the corresponding benzoic acid with the corresponding amine.

Example Compound MP ~C

No.

32 4-Methoxy-N-(4-methoxy-phenyl)-3-nitro-153.5-156 benzamide 33 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-158 benzamide 34 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-102.5-104.5 methyl-benzamide 35 N-Ethyl-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-90-91 benzamide 36 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N,N-oil dimethyl-benzamide 37 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(285-288 tetrazol-5-yl)-benzamide 38 5-Bromo-2-(4-iodo-2-methyl-phenylamino)-180-182 benzamide 39 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N,N-137-138 dimethyl-benzamide 40 [5-Chloro-2-(4-iodo-2-methyl-phenylamino)-170-173 benzoylamino]-acetic acid 41 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-69-71 propyl-benzamide 42 5-Bromo-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-132-133.4 phenylamino)-benzamide 43 N,N-Diethyl-4-fluoro-2-(4-iodo-2-methyl-oil phenylamino)-benzamide 44 4-Fluoro-N-{3-(4-(2-hydroxy-ethyl)-piperazin-1-yl]-122-propyl}-2-(4-iodo-2-methyl-phenylanuno)-benzamide 45 N,N-Diethyl-2-(4-iodo-2-methyl-phenylamino)-91-93 5-nitro-benzamide 46 N-Butyl-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-97-99 benzamide Example Compound MP ~C
No.
47 5-Chloro-N,N-diethyl-2-(4-iodo-2-methyl- 118-120 phenylamino)-benzamide .
48 5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N,N- 142.5-144 dimethyl-benzamide 4-Fluoro-2-(4-iodo-2-methyl=phenylamino)-benzyl alcohol 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid (0.50 g, 1.35 mmol) was dissolved in 6 mL (6 mmol) of cold 1.0 M borane-tetrahydrofuran complex in tetrahydrofuran solution. The reaction mixture was stirred under nitrogen atmosphere at room temperature overnight. The reaction was quenched with 80 mL of methanol. Concentration in vacuo produced a clear tan oil which was purified by MPLC. Elution with dichloromethane afforded 0.4285 g (89%) of a white solid; mp 99-100.5°C;
1 H NMR (400 MHz; DMSO): 8 7.57 (d, 1 H, J=1.7 Hz), 7.45 (dd, 1 H, J=8.4, 1.9 Hz), 7.39 (s, 1 H), 7.29 (t, 1 H, J=7.5 Hz), 6.89 (d, 1 H, J=8.4 Hz), 6.67-6.60 (m, 1 H), 5.47 (t, 1 H, J=5.5 Hz), 4.49 (d, 2H, 5.1 Hz), 2.14 (s, 3H);
1R (KBr) 3372 (O-H stretch) cm-1;
MS (CI) M+1 = 358.
Analysis calculated for C 14H 13FIN0:
C, 47.08; H, 3.67; N, 3.92.
Found: C, 47.17; H, 3.75; N, 3.72.

The following benzyl alcohols were prepared by the general procedure of Example 49.

Example No. Compound MP ~C
50 [5-Chloro-2-(4-iodo-2-methyl-phenylamino)- 82-85 phenyl]-methanol 51 [2-(4-Iodo-2-methyl-phenylamino)-S-nitro-phenyl]- 126.5-128.5 methanol 52 [5-Bromo-2-(4-iodo-2-methyl-phenylamino)- 60.5-63.5 phenyl]-methanol Several invention compounds of Formula I were prepared utilizing combinatorial synthetic techniques. The general procedure is as follows:
To a 0.8-mL autosampler vial in a metal block was added 40 ~tL of a 0.5 M solution of the acid in DMF and 40 pL of the reagent amine (2M solution in Hunig's base and 1 M in amine in DMF). A O.SM solution of PyBrop was freshly prepared and 50 pL were added to the autosampler vial. The reaction was allowed to stand for 24 hours.
The reaction mixture was transferred to a 2-dram vial and diluted with 2 mL of ethyl acetate. The organic layer was washed with 3 mL of distilled water and the water layer washed again with 2 mL of ethyl acetate. The combined organic layers were allowed to evaporate to dryness in an open fume hood.
The residue was taken up in 2 mL of SO% acetonitrile in water and injected on a semi-prep reversed phase column ( 10 mm x 25 cm, 5 p.M spherical silica, pore size i 1 S A derivatized with C-18, the sample was eluted at 4.7 mL/min with a linear ramp to 100% acetonitrile over 8.5 minutes. Elution with 100%
acetonitrile continued for 8 minutes). Fractions were collected by monitoring at 214 nM. The residue was dissolved in chloroform and transferred to a preweighed vial, evaporated, and weighed again to determine the yield.

The following compounds of Formula I were prepared by combinatorial methodology:
Example Compound MS

No. M-H

53 5-Bromo-3,4-difluoro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-510 phenylamino)-benzamide 54 N-(2,3-Dihydroxy-propyl)-3,4-difluoro-2-(4-iodo-2-methyl-462 phenylamino)-benzamide 55 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-577 (2-piperidin-1-yl-ethyl)-benzamide 56 3,4-Difluoro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-432 phenylamino)-benzamide 57 N-(2,3-Dihydroxy-propyl)-4-fluoro-2-(4-iodo-2-methyl-444 phenylamino)-benzamide 58 3,4-Difluoro-N-(3-hydroxy-propyl)-2-(4-iodo-2-methyl-446 phenylamino)-benzamide 59 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-564 (2-pyrrolidin-I -yl-ethyl}-ben-ramide 60 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-571 (2-pyridin-4-yl-ethyl)-benzamide 61 4-Fluoro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-414 benzamide 62 5-Bromo-N-(3-dimethylamino-propyl)-3,4-difluoro-2-(4-iodo-551 2-methyl-phenylamino)-benzamide 63 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-580 (2-morpholin-4-yI-ethyl)-benzamide 64 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-501 4-yl-ethyl)-benzamide 65 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-485 I -yl-ethyl)-benzamide Example Compound MS

No. M-H

66 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyridin-4-yl-493 ethyl)-benzamide 67 N-(3-Dimethylamino-propyl)-3,4-difluoro-2-(4-iodo-2-methyl-473 phenylamino)-benzamide 68 N-Benzyl-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide460 69 2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-hydroxy-384 ethyl)-benzamide 70 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-483 ethyl)-benzamide 71 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-piperidin-1-yl-495 propyl)-benzamide 72 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-piperidin-513 1-yl-propyl)-benzamide 73 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-thiophen-2-yl-480 ethyl)-benzamide 74 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1-yl-467 ethyl)-benzamide 75 2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-morpholin-453 4-yl-ethyl)-benzamide 76 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-pyridin-4-ylmethyl-benzamide 77 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-pyridin-4-ylmethyl-benzamide 78 2-(4-Bromo-2-methyl-phenylamino)-N-(3-dimethylamino-propyl)-425 3,4-difluoro-benzamide 79 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-pyridin-4-ylmethyl-461 benzamide 80 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyridin-4-yl-475 ethyl)-benzamide 81 2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-pyridin-445 4-yl-ethyl)-benzamide 82 2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(3-hydroxy-400 propyl)-benzamide Example Compound No. M-H

83 2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-pyrrolidin-437 1-yl-ethyl)-benzamide 84 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-phenethyl-474 benzamide 85 2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-thiophen-450 2-yl-ethyl)-benzamide 86 2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-pyridin-431 4-ylmethyl-benzamide 87 2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-phenethyl-444 benzamide 88 2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-piperidin-451 1-yl-ethyl)-benzamide 89 5-Chloro-N-{3-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-propyl}-557*

2-(4-iodo-2-methyl-phenylamino)-benzamide 90 5-Fluoro-N-{3-[4-(2-hydroxy-ethyl)-piperazin-l-yl]-propyl}-541*

2-(4-iodo-2-methyl-phenylamino)-benzamide 91 2-(4-Iodo-2-methyl-phenylamino)-5-nitro-N-pyridin-4-yl487 methyl-benzamide 92 5-Bromo-N-{3-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-propyl}-601 2-(4-iodo-2-methyl- phenylamino)-benzamide 93 5-Chloro-N-(2-diethylamino-ethyl)-2-(4-iodo-2-methyl-486*

phenylamino)-benzamide 94 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperidin-1-yl-497*

ethyl)-benzamide 95 (3-Hydroxy-pyrrolidin-1-yl)-[2-(4-iodo-2-methyl-phenylamino)-466 5-nitro-phenyl]-96 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1-yl-484*

ethyl)-benzamide 97 5-Bromo-N-(2-diethylamino-ethyl)-2-(4-iodo-2-methyl-530*

phenylamino)-benzamide 98 N-{2-[Bis-(2-hydroxy-ethyl)-amino]-ethyl}-5-chloro-2-(4-iodo-518*

2-methyl- phenylamino)-benzamide Example Compound MS

No. M-H

99 N-{2-[Bis-(2-hydroxy-ethyl)-amino]-ethyl}-5-bromo-2-(4-iodo-562*

2-methyl- phenylamino)-benzamide 100 [5-Bromo-2-(4-iodo-2-methyl-phenylamino)-phenyl]-(3-hydroxy-499 pyrrolidin-1-yl)-101 2-(4-Iodo-2-methyl-phenylamino)-S-nitro-benzoic501 acid phenethyl ester 102 N-{3-[4-(2-Hydroxy-ethyl)-piperazin-1-yl]-propyl}-2-(4-iodo-568*

2-methyl-phenylamino)-benzamide 103 [S-Chloro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-(3-hydroxy-455 pyrrolidin-1-yl)-104 S-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-pyridin-4-ylmethyl-460 benzamide 105 5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1-yl-528*

ethyl)-benzamide 106 5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperidin-1-yl-542*

ethyl)-benzamide 107 5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1-yl-468*

ethyl)-benzamide 108 5-Chloro-N-(3-dimethylamino-propyl)-2-(4-iodo-2-methyl-472*

phenylamino)-benzamide 109 N-{2-[Bis-(2-hydroxy-ethyl)-amino]-ethyl}-5-fluoro-2-(4-iodo-502*

2-methyl-phenylanuno)-benzamide 110 5-Chloro-N-(3-hydroxy-propyl)-2-(4-iodo-2-methyl-445*

phenylamino)-benzamide 111 5-Chloro-N-(3-diethylamino-2-hydroxy-propyl)-2-(4-iodo-516*

2-methyl-phenylamino)-benzamide 112 5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperidin-1-yl-482*

ethyl)-benzamide 113 5-Bromo-N-(3-hydroxy-propyl)-2-(4-iodo-2-methyl-489*

phenylamino)-benzamide 114 5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(3-piperidin-1-yl-556*

propyl)-benzamide Example Compound MS

No. M-H

115 N-{2-[Bis-(2-hydroxy-ethyl)-amino]-ethyl}-2-(4-iodo-2-methyl-529*

phenylamino)-5-nitro-benzamide 116 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-500*

ethyl)-benzamide 117 5-Chloro-N-(3-diethylamino-propyl)-2-(4-iodo-2-methyl-500*

phenylamino)-benzamide 118 5-Chloro-N-(2-diisopropylamino-ethyl)-2-(4-iodo-2-methyl-514*

phenylamino)-benzamide 119 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(3-piperidin-1-yl-512*

propyl)-benzamide 120 2-(4-Iodo-2-methyl-phenylamino)-5-nitro-N-(2-piperidin-I-yl-509*

ethyl)-benzamide 121 5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperazin-1-yl-544*

ethyl)-benzamide 122 N-(2-Diethylamino-ethyl)-5-fluoro-2-(4-iodo-2-methyl-470*

phenylamino)-benzamide 123 5-Bromo-N-(3-dimethylamino-propyl)-2-(4-iodo-2-methyl-516*

phenylamino)-benzamide 124 N-(3-Hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)-5-nitro-456*

benzamide 125 5-Fluoro-N-(3-hydroxy-propyl)-2-(4-iodo-2-methyl-429*

phenylamino)-benzamide 126 N-(3-Diethylamino-propyl)-5-fluoro-2-(4-iodo-2-methyl-484*

phenylamino)-benzamide 127 N-(3-Diethylamino-propyl)-2-(4-iodo-2-methyl-phenylamino)-511 5-nitro-benzamide 128 5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-544*

ethyl)-benzamide 129 2-(4-Iodo-2-methyl-phenylamino)-5-nitro-N-(3-piperidin-1-yl-523*

propyl)-benzamide I30 [5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-(3-hydroxy-439 pyrrolidin-1-yl)-Example Compound MS

No. M-H

131 5-Bromo-N-(2-diisopropylamino-ethyl)-2-(4-iodo-2-methyl-558*

phenylamino)-benzamide 132 S-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-484*

ethyl)-benzamide 133 5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-piperidin-1-yl-496*

propyl)-benzamide 134 [5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl)-482 [4-(2-hydroxy-ethyl)-piperazin-I -135 N-(3-Diethylamino-2-hydroxy-propyl)-5-fluoro-2-(4-iodo-500*

2-methyl-phenylamino)-benzamide 136 [S-Chloro-2-(4-iodo-2-methyl-phenylamino)-benzoylamino]-443 acetic acid 137 2-(4-Iodo-2-methyl-phenylamino)-S-vitro-N-(2-pyrrolidin-1-yl-495*

ethyl)-benzamide 138 N-(3-Dimethylamino-propyl)-2-(4-iodo-2-methyl-phenylamino)-483*

5-vitro-benzamide 139 N-(2-Diisopropylamino-ethyl)-5-fluoro-2-(4-iodo-2-methyl-498*

phenylamino)-benzamide 140 5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-thiobenzoic490 acid S-phenethyl ester 141 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-thiobenzoic506 acid S-phenethyl ester 142 5-Bromo-2-(4-iodo-2-methyl-phenylamino)-thiobenzoic536 acid S-benzyl ester 143 2-(4-Iodo-2-methyl-phenylamino)-5-vitro-thiobenzoic503 acid S-benzyl ester 144 5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-thiobenzoic476 acid S-benzyl ester 145 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-thiobenzoic492 acid S-benzyl ester 146 N-Cyclopropyl-S-fluoro-2-(4-iodo-2-methyl-phenylamino)-409 benzamide IJxampleCompound MS

No. M-H

147 S-Chloro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-429 benzamide 148 5-Fluoro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-413 benzamide 149 N-Benzyloxy-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-475 benzamide 150 N-Benzyloxy-5-bromo-2-(4-iodo-2-methyl-phenylamino)-593 benzamide I51 2-(4-Iodo-2-methyl-phenylamino)-S-vitro-N-(4-sulfamoyl-567 benzyl)-benzamide 152 5-Bromo-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-473 benramide 153 N-(2-Hydroxy-ethyl)-5-iodo-2-(4-iodo-2-methyl-phenylamino)-521 benzamide 154 N-(2-Hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-5-vitro-440 benzamide 155 2-(4-Iodo-2-methyl-phenylamino)-N-methyl-5-vitro-N-phenyl-486 benzamide 156 5-Chloro-N-cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-425 benzamide 157 5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-459 benzamide 158 N-Allyl-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide409 159 N-Benzyloxy-5-iodo-2-(4-iodo-2-methyl-phenylamino)-583 benzamide 160 5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(4-sulfamoyl-538 benzyl)-benzamide 161 N-Allyl-S-chloro-2-(4-iodo-2-methyl-phenylamino)-benzamide425 162 N-Cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-5-vitro-436 benzamide 163 5-Bromo-N-cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-469 benzamide Example Compound MS

No. M-H

164 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide 165 5-Iodo-2-(4-iodo-2-methyl-phenyiamino)-N-(4-sulfamoyl-benzyl)-646 benzamide 166 5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(4-sulfamoyl-598 benzyl)-benzamide 167 N-Ailyl-2-(4-iodo-2-methyl-phenylamino)-5-vitro-benzamide436 168 2-(4-Iodo-2-methyl-phenylamino)-S-vitro-N-(4-sulfamoyl-565 benzyl)-benzamide 169 N-Allyl-5-bromo-2-(4-iodo-2-methyl-phenylamino)-benzamide469 170 5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-benzyl)-473 benzamide 171 N-Cyclopropyl-5-iodo-2-(4-iodo-2-methyl-phenylamino)-517 benzamide 172 5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide 173 N-Benzyloxy-2-(4-iodo-2-methyl-phenylamino)-S-vitro-502 benzamide 174 N-Cyclohexyl-5-iodo-2-(4-iodo-2-methyl-phenylamino)-559 benzamide 175 N-Allyl-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide517 176 5-Iodo-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-benzyl)-benzamide 177 2-(4-Iodo-2-methyl-phenylamino)-N-(3-methyl-benzyl)-5-vitro-500 benzamide 178 S-Iodo-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide 179 N-Cyclohexyl-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-451 benzamide 180 5-Chloro-N-cyclohexyl-2-(4-iodo-2-methyl-phenylamino)-467 benzamide 181 5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-benzyl)-533 benzamide ExampleCompound MS

No.

M-H

182 S-Bromo-N-cyclohexyl-2-(4-iodo-2-methyl-phenylamino)-S
I
I

benzamide 183 S-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-benzyl)-489 benzamide 184 N-Cyclohexyl-2-(4-iodo-2-methyl-phenylamino}-5-nitro-478 benzamide 185 N-Benzyloxy-5-bromo-2-(4-iodo-2-methyl-phenylamino)-538 benzanude 186 N-Benzyloxy-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-477 benzamide 187 5-Chloro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-431 benzamide 188 5-Bromo-N-(2-hydroxy-ethyl}-2-(4-iodo-2-methyl-phenylanuno)-475 benzamide 189 2-(4-Iodo-2-methyl-phenylamino)-N-methyl-5-vitro-N-phenyl-488 benzamide 190 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-477 benzamide 191 N-(2-Hydroxy-ethyl)-5-iodo-2-(4-iodo-2-methyl-phenylamino}-523 benzamide 192 5-Chloro-N-cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-425 benzarnide 193 N-Allyl-5-chloro-2-(4-iodo-2-methyl-phenylamino)-benzamide427 194 5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-461 benzamide 195 N-(2-Hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-5-vitro-442 benzamide 196 5-Fluoro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-415 benzamide 197 5-Bromo-N-cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-472 benzamide 198 N-Cyclopropyl-S-fluoro-2-(4-iodo-2-methyl-phenylamino)-411 benzamide Example Compound M S
No. M-H
199 5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(4-sulfamoyl- 540 benzyl}-benzamide 200 N-Cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro- 438 benzamide 201 N-Allyl-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide 411 202 N-Benzyloxy-5-iodo-2-(4-iodo-2-methyl-phenylamino)- 585 benzamide 203 N-Allyl-5-bromo-2-(4-iodo-2-methyl-phenylamino)-benzamide 472 204 5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(4-sulfamoyl- 601 benzyl)-benramide 205 5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl- 522 benzamide 206 N-Allyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide 438 * M+H

Preparation of f4-Chloro-2-( 1 H-tetrazol-5-y1~4-iodo-2-methyl-phenyl) amine Step a: Preparation of 5-Chloro-2-fluoro-benzaldehyde To a solution of 1-chloro-4-fluorobenzne ( 13.06 g, 0.1 mol) in THF
(180 mL), at -78°C, LDA (2 M solution in THF, 50 mL, 0.1 mol) was added dropwise. After stirring at -78°C for 1.5 hours, DMF (8 mL) was added to the reaction mixture and allowed to warm up to room temperature overnight. The reaction mixture was partitioned between water and Et20. The Et20 layer was dried (MgS04) and the solvent removed in vacuum to give 14.95 g (94%) yield of crude aldehyde:
1H NMR (CDC13): 8, 10.3 (s, -C(=O)H).
Step b: Preparation of 5-Chloro-2-fluoro-benzaldeh~de oxime A solution of 5-chloro-2-fluoro-benzaldehyde ( 10 g, 0.0631 mol), hydroxylamine hydrochloride (6.57 g, 0.0946 mol) and pyridine (8.3 mL, 0.1010 mol) in EtOH (100 mL) was heated at 75°C (oil bath temperature) for 1 hour and the solvent removed under vacuum to give an oil. The oil was partitioned between water and CH2Cl2. The CH2C12 layer was dried (MgS04) and the solvent removed under vacuum to give crude aldoxime as a solid. The solid was purified by medium pressure liquid chromatography on silica. Elution with CH2Cl2 gave 4.87 g (28%) of the aldoxime as white solid: mp 95-97°C;
Analysis calculated for C7HSNOFCI:
C, 48.44; H, 2.90; N, 8.07.
Found: C, 48.55; H, 2.69, N, 7.90.
Step c: Preparation of 5-Chloro-2-fluoro-benzonirile A solution of the 5-chloro-2-fluoro-benzaldehyde oxime (3.15 g, 0.0182 mol) in acetic anhydride (150 mL) was refluxed for 16 hours. The reaction mixture was cooled to room temperature and poured into saturated aqueous NaHC03 (200 mL) solution. The mixture was extracted with Et20. The Et20 layer was dried (K2C03) and the solvent removed to give the product as an oily solid. The product was used without further purification in the next step.
Step d: Preparation of 5-(S-Chloro-2-fluoro-phenyl)-1H-tetrazole A mixture of 5-chloro-2-fluoro-benzonitrile (2.84 g, 0.01823 mol), butanol (15 mL), sodium azide (1.543 g, 0.0237 mol), acetic acid (1.36 mL, 0.0237 mol) was refluxed for 24 hours. The reaction mixture was cooled to room temperature, additional 1.543 g sodium azide added, and the reaction mixture refluxed for additional 24 hours. After cooling to room temperature, Et20 ( 100 mL) and 10%
aqueous NaOH (200 mL) were added sequentially. The mixture was vigorously stirred. The aqueous layer was separated, cooled with ice-methanol bath (-15°C) and acidified to pH 1 with conc. HCI. A gray solid precipitated. The solid was dried in vacuum at SO°C to give 1.76 g (49%) of 5-(5-chloro-2-fluoro-phenyl)-1H-tetrazole: mp partial melt at 110°C, complete melting at 124°C);
1 H (400 Mz, CDC13): S 8.19-8.08 {m, 1 H), 7.77-7.71 (m, 1 H), 7.61-7.52 (m, 1 H);

13C (100 Mz, CDC13): 8 159.00, 156.49, 140.88, 133.02, 132.93, 130.73, 129.23, 129.21, 129.08, 126.05, 118.96, 118.73, 114.50;
MS (CI) M+1 = 199 (100), M = 198 (6).
Step e: Preparation of f 4-Chloro-2-( 1 H-tetrazol-5-yl)-(4-iodo-~-methyl-phenyl) amine To a solution of 2-methyl-4-iodoaniline (3.52 g, 0.0151 mol) in THF
(25 mL) at -78°C, LDA (2 molar solution in THF, 11.33 mL, 0.02267 mol) was added dropwise. After stirring for 0.5 hours, a solution of I -(tetrazol-5-yl)-2-fluoro-5-chlorobenzene ( 1.5 g, 0.00756 mol) in THF ( 15 mL) was added dropwise. The reaction was stirred for 16 hours as it warmed up to room temperature. The reaction mixture was quenched with aqueous conc. NH4Cl solution and extracted with CH2C12. The organic layer was dried (MgS04) and the solvent removed giving a crude product as an oil. The oil with CH2C12->CH2C12:MeOH (9.7:0.3) gave 1.5 g (48%) of the desired product:
mp 205-208;
1 H (400 Mz, DMSO): 8 9.13 (s, 1 H), 8.00-7.99 (s, 1 H), 7.69 (s, 1 H), 7.55-7.52 (m, 1H), 7.43-7.40 (m, 1H), 7.12-7.05 {m, 1H), 2.24 (s, 3H);
13C (100 Mz, CDCl3): S 141.87, 139.28, 138.88, 135.47, 133.71, 131.65, 128.15, 123.69, 121.94, 116.68, 87.79, 17.22;
MS (CI) M+2 = 413 (44), M+1 = 412 (85), M = 411 ( 100).
Analysis calculated for C14H11N5C1I~O.SH20:
C, 39.97; H, 2.87; N, 16.65.
Found: C, 38.87, H, 2.77; N, 16.47.
The following tetrazole substituted phenylamines were prepared by following the general procedure of Example 207.

(4-Iodo-2-methyl-phenyl)-f 2-l1 H-tetrazol-5-yl)-phenyljamine, mp 231 °C (dec) f 4-Nitro-2-( 1 H-tetrazol-S-yl)-(4-iodo-2-methyl-phenyl)-amine, mp 205-208°C.
The invention compounds are useful in treating cancer and other proliferative diseases by virtue of their selective inhibition of the dual specificity protein kinases MEKI and MEK2. The invention compound has been evaluated in a number of biological assays which are normally utilized to establish inhibition of proteins and kinases, and to measure mitogenic and metabolic responses to such inhibition.

Additional invention compounds which were prepared by the general methods described above are:
Example Compound MP °C
No.
210 2-(2-Chloro-4-iodo-phenylamino)-3-fluoro-4-(2-239-241 DEC

morpholin-4-yl-ethylamino)-5-nitro-benzoic acid 211 4-Amino-2-(2-chloro-4-iodo-phenylamino)-3-fluoro->270 5-nitro-benzoic acid 2I2 2,4-Bis-(2-chloro-4-iodo-phenylamino)-3-fluoro-5->265 DEC

nitro-benzoic acid 213 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-5-nitro-218-225 DEC

benzoic acid 214 2-(2,6-Difluoro-4-iodo-phenylamino)-3,4-difluoro-247-249 benzoic acid 215 2-(2-Chloro-4-iodo-phenylamino)-4-nitro-benzoic267-269 acid 216 2-(2,4-Diiodo-phenylamino)-4-fluoro-benzoic260-261 acid 217 2-(2-Bromo-4-iodo-phenylamino)-4-fluoro-benzoic259-262 acid 218 4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-benzoic215-217 acid Example Compound MP ~C
No.
219 2-(2-Chloro-4-iodo-phenylamino}-4-fluoro-benzoic 242-247 acid 220 S-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-312.5-318 difluoro-benzoic acid 221 2,3,5-Trifluoro-6-(4-iodo-2-methyl-phenylamino)-4-118-121 (4-methyl-piperazin-1-yl)-benzoic acid methyl ester dihydrofluoride salt 222 S-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-214-217 DEC

phenylamino)-N-(4-methyl-piperazin-1-yl)-benazmide 223 S-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-154-17S
DEC

phenylamino)-benzoic acid N',N'-dimethyl-hydrazide 224 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic1S3.S-1S6 acid hydrazide Enzyme Assays Cascade assay for inhibitors of the MAP kinase pathway Incorporation of 32P into myelin basic protein (MBP) was assayed in the presence of a glutathione S-transferase fusion protein containing p44MAP
kinase S (GST-MAPK) and a glutathione S-transferase fusion protein containing p4SMEK
(GST-MEK). T'he assay solution contained 20 mM HEPES, pH 7.4, mM MgCl2, 1 mM MnCl2, 1 mM EGTA, SO p.M ['y 32P]ATP, 10 p.g GST-MEK, 0.5 ~tg GST-MAPK and 40 p.g MBP in a final volume of 100 ~.L.
Reactions were stopped after 20 minutes by addition of trichloroacetic acid and 10 filtered through a GF/C filter mat. 32P retained on the filter mat was determined using a 1205 Betaplate. Compounds were assessed at 10 ~tM for ability to inhibit incorporation of 32p, To ascertain whether compounds were inhibiting GST-MEK or GST
MAPK, two additional protocols were employed. In the first protocol, compounds were added to tubes containing GST-MEK, followed by addition of GST-MAPK, MBP and [y-32P]ATP. In the second protocol, compounds were added to tubes containing both GST-MEK and GST-MAPK, followed by MBP and [7 32p]ATP.
Compounds that showed activity in both protocols were scored as MAPK
inhibitors, while compounds showing activity in only the first protocol were scored as MEK inhibitors.
In vitro MAP kinase assay Inhibitory activity was also confirmed in direct assays. For MAP kinase, 1 ~g GST-MAPK was incubated with 40 ~.g MBP for 15 minutes at 30°C in a final volume of 50 pL containing 50 mM Tris (pH 7.5), 10 ~,M MgCl2, 2 ~M
EGTA, and 10 p.M [y 32P]ATP. The reaction was stopped by addition of Laemmli SDS sample buffer and phosphorylated MBP resolved by electrophoresis on a 10% polyacrylamide gel. Radioactivity incorporated into MBP was determined by autoradiography, and subsequently by excision of the bands followed by scintillation counting.
In vitro MEK assay For evaluation of direct MEK activity, 10 pg GST-MEKI was incubated with 5 p.g of a glutathione S-transferase fusion protein containing p44MAP
kinase with a lysine to alanine mutation at position 71 (GST-MAPK-KA). T'his mutation eliminates kinase activity of MAPK, so only kinase activity attributed to the added MEK remains. Incubations were 15 minutes at 30°C in a final volume of 50 ~,L
containing 50 mM Tris (pH 7.5), 10 ~M MgCl2, 2 ~.M EGTA, and 10 ~.M
[.~-32p]ATP. The reaction was stopped by addition of Laemmli SDS sample buffer and phosphorylated GST-MAPK-KA was resolved by electrophoresis on a 10% polyacrylamide gel. Radioactivity incorporated into GST-MAPK-KA was determined by autoradiography, and subsequently by excision of the bands followed by scintillation counting. Additionally, an artificially activated MEK was utilized that contained serine to glutamate mutations at positions 218 and 222 (GST-MEK-2E). When these sites are phosphorylated, MEK activity is increased. Phosphorylation of these sites can be mimicked by mutation of the serine residues to glutamate. For this assay, 5 ~tg GST-MEK-2E was incubated with 5 p.g GST-MAPK-KA for 15 minutes at 30°C in the same reaction buffer as described above. Reactions were terminated and analyzed as above.
Whole cell MAP kinase assay To determine if compounds were able to block activation of MAP kinase in whole cells, the following protocol was used: Cells were plated in multi-well plates and grown to confluence. Cells were then serum-deprived overnight.
Cells were exposed to the desired concentrations of compound or vehicle (DMSO) for 30 minutes, followed by addition of a growth factor, for example, PDGF
(100 ng/mL). After a 5-minute treatment with the growth factor, cells were washed with PBS, then lysed in a buffer consisting of 70 mM NaCI, 10 mM
HEPES (pH 7.4), 50 mM glycerol phosphate, and 1 % Triton X-100. Lysates were clarified by centrifugation at 13,000 x g for 10 minutes. Five micrograms of the resulting supernatants were incubated with 10 pg microtubule associated protein-2 (Map2) for 15 minutes at 30°C in a final volume of 25 ~.L
containing 50 mM Tris (pH 7.4), 10 mM MgCl2, 2 mM EGTA and 30 ~M [y 32P]ATP.
Reactions were terminated by addition of Laemmli sample buffer. Phosphorylated Map2 was resolved on 7.5% acrylamide gels and incorporated radioactivity determined by autoradiography and subsequent excision of the bands followed by scintillation counting.
Immunoprecipitation and antiphosnhotyrosine immunoblots To determine the state of tyrosine phosphorylation of cellular MAP kinase, cells were lysed, endogenous MAP kinase was immunoprecipitated with a specific antibody, and the resulting immunoprecipitate analyzed for the presence of phosphotyrosine as follows: confluent cells were serum-deprived overnight and treated with compounds and growth factors as described above. Cells were then scraped and pelleted at 13,000 x g for 2 minutes. The resulting cell pellet was resuspended and dissolved in 100 p,L of 1 % SDS containing 1 mM NaV04.
Following alternate boiling and vortexing to denature cellular protein, 900 ~L

RIPA buffer (50 mM Tris (pH 7.4), 150 mM NaCI, 1 % Triton X-I00, 0.1 deoxycholate, and 10 mM EDTA) was added. To this mixture was added 60 ~.L
agarose beads coupled with rabbit immunoglobulin G and 60 pL Pansorbin cells in order to clear the lysate of nonspecific binding proteins. This mixture was incubated at 4°C for 1 S minutes then centrifuged at 13,000 x g for 10 minutes.
The resulting supernatant was transferred to fresh tubes and incubated with 10 pL
of a polyclonal antisera raised against a fragment of MAP kinase for a minimum of 1 hour at 4°C. Seventy microliters of a slurry of agarose beads coupled with protein G and protein A was added and the incubation continued for an additional 30 minutes at 4°C. The beads were pelleted by centrifugation at 13,000 x g for 5 minutes and washed three times with 1 mL RIPA buffer. Laemmli sample buffer was added to the final bead pellet. This mixture was boiled for S minutes then resolved on a 10% acrylamide gel. Proteins on the gel were transferred to a nitrocellulose membrane and nonspecific binding sites on the membrane blocked by incubation with 1 % ovalbumin and 1 % bovine serum albumin in TBST
(150 mM NaCI, 10 mM Tris (pH 7.4), and 0.05% Tween 20). The membrane was then incubated with a commercially available antibody directed against phosphotyrosine. Antibody bound on the membrane was detected by incubation with 1251_protein A, followed by autoradiography.
Cell Growth Assays 3H-Thymidine incorporation Cells were plated in mufti-well plates and grown to near confluence. The media was then removed and replaced with growth media containing 1 % bovine serum albumin. After 24-hour serum starvation, compounds and specific growth factors were added and incubations continued for an additional 24 hours.
During the final 2 hours, 3H-thymidine was added to the medium. To terminate the incubations, the medium was removed and cell layers washed twice with ice-cold phosphate-buffered saline. After the final wash, ice-cold 5% trichloroacetic acid was added and the cells incubated for I 5 minutes at room temperature. The trichloroacetic acid solution was then removed and the cell layer washed three times with distilled water. After the final wash, the cell layer was solubilized by addition of 2% sodium dodecylsulfate. Radioactivity in this solution was determined by scintillation counting.
In 3T3-L1 adipocyte cells, in which the inhibition blocks MAPK
activation by insulin with an ICSp of 3 ~.M, the compound had no effect on the insulin stimulated uptake of radiolabeled 2-deoxyglucose, or on the insulin-stimulated synthesis of either lipid or glycogen at 10 ~M concentration. This demonstrates that the inhibitor shows selectivity between the mitogenic and metabolic effects of insulin, and demonstrates that the inhibitor will show less toxicity than an inhibitor which does not show this surprising selectivity.
Monolayer growth Cells were plated into multi-well plates at 10 to 20,000 cells/mL.
Forty-eight hours after seeding, compounds were added to the cell growth medium and incubation was continued for 2 additional days. Cells were then removed from the wells by incubation with trypsin and enumerated with a Coulter counter.
Growth in soft-agar Cells were seeded into 35-mm dishes at 5 to 10,000 cells/dish using growth medium containing 0.3% agar. After chilling to solidify the agar, cells were transferred to a 37°C incubator. After 7 to 10 days growth, visible colonies were manually enumerated with the aid of a dissecting microscope.
Order of addition experiments established that the invention compounds are inhibiting MEK and not MAP kinase. Experiments looking at the phosphorylation of a kinase defective mutant of MAP kinase as substrate (so that there can be no autophosphorylation of the MAP kinase to complicate interpretation) confirms that the inhibitor inhibits MEK with an IC50 essentially identical to that produced in the cascade assay.
Kinetic analysis demonstrates that the invention compounds are not competitive with ATP. Thus, they do not bind at the ATP binding site of the enzyme, which is probably the explanation as to why these compounds do not w0 99/01421 PCT/US98/13105 show the nonspecific kinase inhibitory activity typical of most kinase inhibitors, which do bind at the ATP binding site and which are ATP competitive.
The in vitro and in vivo biological activity of several representative compounds of Formula I in the foregoing assays is presented in Table I .
Table 1 Compound In Vitro In Vivo of (Cell Culture) Example % Inhibition IC50% InhibitionIC50 No. pM ~M

1 0.019 2 0.014 3 3 0.0111 10 4 0.005 1 0.066 6 0.071 7 0.072 8 0.086 9 0.097 0.101 11 0.128 12 0.135 13 0.178 14 0.179 0.194 16 0.323 17 0.434 I 8 0.446 19 0.524 50% at 30 ~tM

0.557 21 0.569 22 1.581 30% at 30 fiM

23 1.588 24 I .944 2.363 26 2.609 50% at 30 l.lM

Table 1 Compound In Vitro In Vivo (Cell Culture) of Example % Inhibition IC50% Inhibition IC50 No. ~M p.M

27 2.269 28 3.670 29 5.331 31 0.226 32 0.028 33 0.052 34 0.098 35 0.121 36 0.129 37 0.237 38 0.412 39 0.497 40 0.651 30% at 30 ~.iM

41 0.872 42 0.920 43 > 1.000 44 1.481 45 1.755 46 1.814 47 1.91 I

48 1.945 49 0.418 3 50. 0.179 51 0.887 52 2.346 53 0.047 0.54 54 0.158 55 0.114 57 0.399 89 0.186 89 0.614 Table 1 Compound In Vitro In Vivo (Cell Culture) of Example % Inhibition 1C50 ~tM % Inhibition No. IC50 uM

90 0.604 91 2.071 92 0.253 93 0.521 95 1.001 96 0.374 100 1.994 184 0.278 186 0.555 187 0.561 188 0.771 189 0.859 190 0.921 191 1.355 192 1.797 193 2.902 194 4.952 195 12.831 208 1.215 209 1.372 211 >0.1 212 0.034 213 0.062 214 0.303 215 0.031 216 1.000 217 >1.00 218 0.051 219 0.108 220 0.029 221 0.002 Table 1 Compound of In Vitro In Vivo (Cell Culture) Example No. % Inhibition IC50 ~M % Inhibition 1C50 ~.M
222 0.085 223 0.043 224 0.028 The invention compounds will be utilized to treat subjects suffering from cancer and other proliferative diseases, immunodeficiency, and certain degenerative diseases, and in need of treatment. The compounds are ideally suited to treating psoriasis, restenosis, autoimmune disease, and atherosclerosis.
The compounds will generally be utilized as a pharmaceutical formulation, in which the compound of Formula I is present in a concentration of about 5% to about 95% by weight. The compounds can be formulated for convenient oral, parenteral, topical, rectal, or like routes of administration. The compound will be formulated with common diluents, excipients, and carriers routinely utilized in medicine, for instance, with polyols such as glycerin, ethylene glycol, sorbitol 70; mono-and difatty acid esters of ethylene glycol. Starches and sugars such as corn starch, sucrose, lactose, and the like, can be utilized for solid preparations. Such solid formulations can be in the form of tablets, troches, pills, capsules, and the like.
Flavoring agents such as peppermint, oil of wintergreen, and the like can be I S incorporated.
Typical doses of active compound are those that are effective to treat the cancer or other proliferative disorder afflicting the mammal. Doses will generally be from about 0.1 mg per kilogram body weight to about 500 mg per kilogram body weight. Such doses will be administered from one to about four times a day, or as needed to effectively treat the cancer, psoriasis, restenosis, or other proliferative disorder.
A preferred method for delivering the invention compound is orally via a tablet, capsule, solution, or syrup. Another method is parenterally, especially via intravenous infusion of a solution of the benzopyran in isotonic saline or S%
aqueous glucose.

Following are typical formulations provided by the invention.

Preparation of 50-mg Tablets Per Tablet Per 10,000 Tablets 0.050 g 4-fluoro-2-(4-iodo-2-methyl- 500 g phenylamino)-benzoic acid 0.080 g lactose 800 g 0.010 g corn starch (for mix) 100 g 0.008 g corn starch (for paste) g0 g 0.002 g magnesium stearate ( 1 %) 20 g 0.150 g 1 S00 g The benzoic acid, lactose, and corn starch (for mix) are blended to uniformity. The corn starch (for paste) is suspended in 600 mL of water and heated with stirring to form a paste. The paste is used to granulate the mixed S powders. The granules are passed through a #8 screen and dried at 120°F. The dry granules are passed through a #16 screen. The mixture is lubricated with 1%
magnesium stearate and compressed into tablets. The tablets are administered to a mammal for inhibiting MEK enzymes and treating restenosis, atherosclerosis, and psoriasis.

Preparation of Oral Suspension Ingredient Amount 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N- 500 mg (methyl)-benzamide Sorbitol solution (70% NF) 40 mL
Sodium benzoate 150 mg Saccharin 10 mg Red dye 10 mg Cherry flavor 50 mg Distilled water qs ad 100 mL

The sorbitol solution is added to 40 mL of distilled water and the benzamide derivative is suspended therein. The saccharin, sodium benzoate, flavor, and dye are added and dissolved. The volume is adjusted to 100 mL with distilled water. Each milliliter of syrup contains S mg of the invention compound.
The syrup is administered to a mammal for treating proliferative disease, especially breast cancer and skin cancer.

Preparation of Parenteral Solution In a solution of 700 mL of propylene glycol and 200 mL of water for injection is added 20.0 g of 4-fluoro-2-(4-bromo-2-methyl-phenylamino)-benzyl alcohol. The volume of the solution is adjusted to 1000 mL by addition of water for injection. The formulation is heat sterilized, filled into 50-mL ampoules each containing 2.0 mL (40 mg of 4-fluoro-2-(4-bromo-2-methyl-phenylamino)-benzyl), and sealed under nitrogen.
The invention compound thus formulated will be administered to a mammal in need of treatment for a proliferative disorder such as cancer, psoriasis, restenosis, atherosclerosis, autoimmune disease, and other immunodeficient diseases and degenerative disorders, at a rate and dose effective to treat the condition. An "antiproliferative amount" of an invention compound is that quantity of compound that inhibits or reduces the rate of proliferation of target cells. Typical cancers to be treated according to this invention include breast cancer, colon cancer, prostate cancer, skin cancer, and the like. The invention compound is especially well-suited for use in combination with'radiation for treating cancer. The compound is well-suited to the treatment of psoriasis, restenosis, and atherosclerosis, and to inhibiting the activity of MEK
enzymes, especially MEK1 and MEK2. All that is required to inhibit these enzymes is to administer to a mammal an MEK inhibiting amount of a compound of the invention. An "MEK inhibiting amount" of an invention compound is an amount that when administered to a mammal causes a measurable inhibition of the MEK
enzyme. Typical MEK inhibiting amounts will be from about 0.1 ~.g to about 500 mg of active compound per kilogram body weight. For treating the proliferative diseases mentioned above, typical doses will be from about 0. i to about 50 mg/kg, normally given from one to about four times per day.

Claims (34)

We claim:
1. The compounds of Formula I

wherein:
R1 is hydrogen, hydroxy, C1-C8 alkyl, C1-C8 alkoxy, halo, trifluoromethyl, or CN;
R2 is hydrogen;
R3, R4, and R5 independently are hydrogen, hydroxy, halo, trifluoromethyl, C1-C8 alkyl, C1-C8 alkoxy, nitro, CN, or -(O or NH)m-(CH2)n-R9, where R9 is hydrogen, hydroxy, COOH, or NR10R11;
n is 0-4;
m is 0 or 1;
R10 and R11 independently are hydrogen or C1-C8 alkyl, or taken together with the nitrogen to which they are attached can complete a 3-10 member cyclic ring optionally containing 1, 2, or 3 additional heteroatoms selected from O, S, NH, or N-C1-C8 alkyl;
Z is COOR7, tetrazolyl, CONR6R7, CONHNR10R11, or CH2OR7;
R6 and R7 independently are hydrogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, alkyl, aryl, heteroaryl, C3-C10 cycloalkyl, or C3-C10 (cycloalkyl optionally containing one, two, or three heteroatoms selected from O, S, NH, or N alkyl);
or R6 and R7 together with the nitrogen to which they are attached complete a 3-10 member cyclic ring optionally containing 1, 2, or 3 additional heteroatoms selected from O, S, NH, or N alkyl;
and wherein any of the foregoing alkyl, alkenyl, and alkynyl groups can be unsubstituted or substituted by halo, hydroxy, alkoxy, amino, alkylamino, dialkylamino, cycloalkyl, aryl, aryloxy, heteroaryl, or heteroaryloxy, and the pharmaceutically acceptable salts thereof.
2. A compound according to Claim 1 wherein R1 is CH3 or halo.
3. A compound according to Claim 2 wherein Z is COOR7, tetrazolyl, or a salt thereof.
4. A compound according to Claim 3 which is [4-Chloro-2-(1H-tetrazol-5-yl)-(4-iodo-2-methyl-phenyl)-amine;
(4-Iodo-2-methyl-phenyl)-[2-(1H-tetrazol-5-yl)-phenyl]amine; and [4-Nitro-2-(1H-tetrazol-5-yl}-(4-iodo-2-methyl-phenyl)-amine.
5. A compound according to Claim 3 having the formula
6. A compound of Claim 5 wherein R3 is hydrogen, fluoro, or chloro; R4 is hydrogen, fluoro, chloro, or nitro; and R5 is hydrogen, chloro, fluoro, bromo, nitro, or methoxy.
7. A compound of Claim 6 which is 4-Fluoro-2-(4-iodo-2-methylphenylamino)benzoic acid;
3,4,5-Trifluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid;
3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid;
5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid;
5-Chloro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid;
Sodium 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-benzoate;
5-Bromo-2-(4-iodo-2-methyl-phenylamino)-benzoic acid;
2-(4-Iodo-2-methyl-phenylamino)-5-nitro-benzoic acid;
4-Chloro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid;
2-(4-Iodo-2-methyl-phenylamino)-benzoic acid;
5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid;
5-Iodo-2-(4-iodo-2-methyl-phenylamino)-benzoic acid;
2,3,5-Trifluoro-4-(4-iodo-2-methyl-phenylamino)-benzoic acid;
2-(4-Iodo-phenylamino)-5-methoxy-benzoic acid;
5-Methyl-2-(4-iodo-2-methyl-phenylamino)-benzoic acid;
2-(4-Iodo-2-methyl-phenylamino)-4-nitro-benzoic acid;
4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzoic acid;
2,3,5-Trifluoro-6-(4-iodo-2-methyl-phenylamino)-4-(4-methyl-piperazin-1-yl)-benzoic acid methyl ester dihydrofluoride salt;
5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(4-methyl-piperazin-1-yl)-benazmide;
5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid N',N'-dimethyl-hydrazide; and 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid hydrazide.
8. A compound of Claim 3 having the formula
9. A compound of Claim 8 wherein R3 is hydrogen, chloro, or fluoro; R4 is hydrogen, chloro, fluoro, or nitro; R5 is hydrogen, chloro, fluoro, bromo, nitro, or methoxy.
10. A compound of Claim 1 which is 2-(4-Bromo-2-methyl-phenylamino)-4-fluoro-benzoic acid;
2-(2-Bromo-4-iodo-phenylamino)-5-nitro-benzoic acid;
2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-benzoic acid;
2-(2-Chloro-4-iodo-phenylamino)-3-fluoro-4-(2-morpholin-4-yl-ethylamino}-5-nitro-benzoic acid;
4-Amino-2-(2-chloro-4-iodo-phenylamino)-3-fluoro-5-nitro-benzoic acid;
2,4-Bis-(2-chloro-4-iodo-phenylamino)-3-fluoro-5-nitro-benzoic acid;
2-(2-Chloro-4-iodo-phenylamino)-4-nitro-benzoic acid;
2-(2,4-Diiodo-phenylamino)-4-fluoro-benzoic acid;
2-(2-Bromo-4-iodo-phenylamino)-4-fluoro-benzoic acid;
4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-benzoic acid;
2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-benzoic acid; and 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-benzoic acid.
11. A compound of Claim 2 wherein Z is CONR6R7.
12. A compound of Claim 11 having the formula
13. A compound of Claim 12 wherein R3 is hydrogen, chloro, or fluoro; R4 is hydrogen, chloro, fluoro, or nitro; and R5 is hydrogen, chloro, fluoro, bromo, nitro, or methoxy.
14. A compound of Claim 13 which is 5-Chloro-N-(2-hydroxyethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-methyl-benzamide;
N-Ethyl-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N,N-dimethyl-benzamide;
4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(1H-tetrazol-5-yl)-benzamide;
5-Bromo-2-(4-iodo-2-methyl-phenylamino)-benzamide;
5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N,N-dimethyl-benzamide;
[5-Chloro-2-(4-iodo-2-methyl-phenylamino)-benzoylamino]-acetic acid;
4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-propyl-benzamide;
5-Bromo-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
N,N-Diethyl-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
4-Fluoro-N-{3-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-propyl}-2-(4-iodo-2-methyl-phenylamino)-benzamide;
N,N-Diethyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide;

N-Butyl-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
5-Chloro-N,N-diethyl-2-(4-iodo-2-methyl-phenylamino)-benzamide;
5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N,N-dimethyl-benzamide;
5-Bromo-3,4-difluoro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino}-benzamide;
N-(2,3-Dihydroxy-propyl)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino}-N-(2-piperidin-1-yl-ethyl)-benzamide;
3,4-Difluoro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
N-(2,3-Dihydroxy-propyl)-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
3,4-Difluoro-N-(3-hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide;
5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyridin-4-yl-ethyl)-benzamide;
4-Fluoro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
5-Bromo-N-(3-dimethylamino-propyl)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethyl)-benzamide;
3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethyl)-benzamide;
3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide;
3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyridin-4-y1-ethyl)-benzamide;
N-(3-Dimethylamino-propyl)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;

N-Benzyl-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-hydroxy-ethyl)-benzamide;
4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethyl)-benzamide;
4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-piperidin-1-yl-propyl)-benzamide;
3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-piperidin-1-yl-propyl)-benzamide;
4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-thiophen-2-yl-ethyl)-benzamide;
4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide;
2-(4-Bromo-2-methyl-phenylamino}-3,4-difluoro-N-(2-morpholin-4-yl-ethyl)-benzamide;
5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-pyridin-4-ylmethyl-benzamide;
3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-pyridin-4-ylmethyl-benzamide;
2-(4-Bromo-2-methyl-phenylamino)-N-(3-dimethylamino-propyl)-3,4-difluoro-benzamide;
4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-pyridin-4-ylmethyl-benzamide;
4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyridin-4-yl-ethyl)-benzamide;
2-{4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-pyridin-4-yl-ethyl)-benzamide;
2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(3-hydroxy-propyl)-benzamide;
2-(4-Bromo-2-methyl-phenylamino}-3,4-difluoro-N-(2-pyrrolidin-1-yl-ethyl)-benzamide;
4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-phenethyl-benzamide;

2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-thiophen-2-yl-ethyl)-benzamide;
2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-pyridin-4-ylmethyl-benzamide;
2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-phenethyl-benzamide;
2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-piperidin-1-yl-ethyl)-benzamide;
5-Chloro-N-{3-[4-(2-hydroxy-ethyl}-piperazin-1-yl]-propyl}-2-(4-iodo-2-methyl-phenylamino)-benzamide;
5-Fluoro-N-{3-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-propyl}-2-(4-iodo-2-methyl- phenylamino)-benzamide;
2-(4-Iodo-2-methyl-phenylamino)-5-nitro-N-pyridin-4-y1 methyl-benzamide;
5-Bromo-N-{3-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-propyl}-2-(4-iodo-2-methyl-phenylamino)-benzamide;
5-Chloro-N-(2-diethylamino-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperidin-1-yl-ethyl)-benzamide;
(3-Hydroxy-pyrrolidin-1-yl)-[2-(4-iodo-2-methyl-phenylamino)-5-nitro-phenyl];
5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide;
5-Bromo-N-(2-diethylamino-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
N-{2-[Bis-(2-hydroxy-ethyl)-amino]-ethyl}-5-chloro-2-(4-iodo-2-methyl-phenylamino)- benzamide;
N-{2-[Bis-(2-hydroxy-ethyl)-amino]-ethyl}-5-bromo-2-(4-iodo-2-methyl-phenylamino)- benzamide;
N-{3-[4-(2-Hydroxy-ethyl)-piperazin-1-yl]-propyl}-2-(4-iodo-2-methyl-phenylamino)- benzamide;
5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-pyridin-4-ylmethyl-benzamide;

5-Bromo-2-(4-iodo-2-ethyl-phenylamino)-N-{2-pyrrolidin-1-yl-ethyl)-benzamide;
5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperidin-1-yl-ethyl)-benzamide;
5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide;
5-Chloro-N-(3-dimethylamino-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
N-{2-[Bis-(2-hydroxy-ethyl)-amino]-ethyl}-5-fluoro-2-(4-iodo-2-methyl-phenylamino)- benzamide;
5-Chloro-N-(3-hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
5-Chloro-N-(3-diethylamino-2-hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)- benzamide;
5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperidin-1-yl-ethyl)-benzamide;
5-Bromo-N-(3-hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
5-Bromo-2-(4-iodo-2-methyl-phenylamino}-N-(3-piperidin-1-yl-propyl)-benzamide;
N-{2-[Bis-(2-hydroxy-ethyl)-amino]-ethyl}-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide;
5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethyl)-benzamide;
5-Chloro-N-(3-diethylamino-propyl}-2-(4-iodo-2-methyl-phenylamino)-benzamide;
5-Chloro-N-(2-diisopropylamino-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(3-piperidin-1-yl-propyl)-benzamide;
2-(4-Iodo-2-methyl-phenylamino)-5-nitro-N-(2-piperidin-1-yl-ethyl)-benzamide;

5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperazin-1-yl-ethyl)-benzamide;
N-(2-Diethylamino-ethyl)-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
5-Bromo-N-(3-dimethylamino-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
N-(3-Hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide;
5-Fluoro-N-(3-hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
N-(3-Diethylamino-propyl)-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
N-(3-Diethylamino-propyl)-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide;
5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethyl)-benzamide;
2-(4-Iodo-2-methyl-phenylamino)-S-nitro-N-(3-piperidin-1-yl-propyl)-benzamide;
[5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-(3-hydroxy-pyrrolidin-1-yl)-;
5-Bromo-N-(2-diisopropylamino-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethyl)-benzamide;
5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-piperidin-1-yl-propyl)-benzamide;
[5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-[4-(2-hydroxy-ethyl)-piperazin-1-;
N-(3-Diethylamino-2-hydroxy-propyl)-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
N-Cyclopropyl-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
5-Chloro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;

5-Fluoro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
N-Benzyloxy-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
N-Benzyloxy-5-bromo-2-(4-iodo-2-methyl-phenylamino)-benzamide;
2-(4-Iodo-2-methyl-phenylamino)-5-nitro-N-(4-sulfamoyl-benzyl)-benzamide;
5-Bromo-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
N-(2-Hydroxy-ethyl)-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide;
N-(2-Hydroxy-ethyl)-2-(4-iodo-2-ethyl-phenylamino)-5-nitro-benzamide;
2-(4-Iodo-2-methyl-phenylamino)-N-methyl-5-nitro-N-phenyl-benzamide;
5-Chloro-N-cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-benzamide;
5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide;
N-Allyl-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
N-Benzyloxy-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide;
5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(4-sulfamoyl-benzyl)-benzamide;
N-Allyl-5-chloro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
N-Cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide;
5-Bromo-N-cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-benzamide;
5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide;
5-Iodo-2-(4-iodo-2-methyl-phenylamino)-N-(4-sulfamoyl-benzyl)-benzamide;
5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(4-sulfamoyl-benzyl)-benzamide;
N-Allyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide;
2-(4-Iodo-2-methyl-phenylamino)-5-nitro-N-(4-sulfamoyl-benzyl)benzamide;
N-Allyl-5-bromo-2-(4-iodo-2-methyl-phenylamino)-benzamide;

5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-benzyl)-benzamide;
N-Cyclopropyl-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide;
5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide;
N-Benzyloxy-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide;
N-Cyclohexyl-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide;
N-Allyl-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide;
5-Iodo-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-benzyl)-benzamide;
2-(4-Iodo-2-methyl-phenylamino)-N-(3-methyl-benzyl)-5-nitro-benzamide;
5-Iodo-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide;
N-Cyclohexyl-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
5-Chloro-N-cyclohexyl-2-(4-iodo-2-methyl-phenylamino)-benzamide;
5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-benzyl)-benzamide;
5-Bromo-N-cyclohexyl-2-(4-iodo-2-methyl-phenylamino)-benzamide;
5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-benzyl)-benzamide;
N-Cyclohexyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide;
N-Benzyloxy-5-bromo-2-(4-iodo-2-methyl-phenylamino)-benzamide;
N-Benzyloxy-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
5-Chloro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
5-Bromo-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
2-(4-Iodo-2-methyl-phenylamino)-N-methyl-5-nitro-N-phenyl-benzamide;
5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide;
N-(2-Hydroxy-ethyl)-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide;
5-Chloro-N-cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-benzamide;

N-Allyl-5-chloro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide;
N-(2-Hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide;
5-Fluoro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
5-Bromo-N-cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-benzamide;
N-Cyclopropyl-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(4-sulfamoyl-benzyl)-benzamide;
N-Cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide;
N-Allyl-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
N-Benzyloxy-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide;
N-Allyl-5-bromo-2-(4-iodo-2-methyl-phenylamino)-benzamide;
5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(4-sulfamoyl-benzyl)-benzamide;
5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide;
and N-Allyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide.
15. A compound of Claim 2 wherein Z is CH2OR7.
16. A compound of Claim 15 having the formula
17. A compound of Claim 16 wherein: R3 is hydrogen, chloro, or fluoro; R4 is hydrogen, chloro, fluoro, or nitro; and R5 is hydrogen, chloro, fluoro, bromo, nitro, or methoxy.
18. A compound of Claim 17 which is 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-benzyl alcohol;
[5-Chloro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-methanol;
[2-(4-Iodo-2-methyl-phenylamino)-5-nitro-phenyl]-methanol; and [5-Bromo-2-(4-iodo-2-methyl-phenylamino)-phenyl]-methanol.
19. A pharmaceutical formulation comprising a compound of Claim 1 together with a pharmaceutically acceptable excipient, diluent, or carrier.
20. A formulation of Claim 19 comprising a compound wherein Z is COOH or a salt thereof.
21. A formulation of Claim 19 comprising a compound wherein Z is CONR6R7.
22. A formulation of Claim 19 comprising a compound wherein Z is CH2OR7.
23. A method for inhibiting MEK enzymes in a mammal comprising administering an MEK inhibiting amount of a compound in Claim 1.
24. A method of treating a mammal suffering from a proliferative disease and in need of treatment comprising administering an antiproliferative amount of a compound of Claim 1.
25. A method according to Claim 21 wherein the proliferative disease is psoriasis, restenosis, autoimmune disease, or atherosclerosis.
26. A method according to Claim 21 wherein the proliferative disease is cancer.
27. A method for treating a mammal suffering from stroke and in need of treatment comprising administering an effective amount of a compound of Claim 1.
28. A method for treating a mammal suffering from heart failure and in need of treatment comprising administering an effective amount of a compound of Claim 1.
29. A method for treating a mammal suffering from hepatomegaly and in need of treatment comprising administering an effective amount of a compound of Claim 1.
30. A method for treating a mammal suffering from cardiomegaly and in need of treatment comprising administering an effective amount of a compound of Claim 1.
31. A method for treating a mammal suffering from diabetes and in need of treatment comprising administering an effective amount of a compound of Claim 1.
32. A method for treating a mammal suffering from Alzheimer's disease and in need of treatment comprising administering an effective amount of a compound of Claim 1.
33. A method for treating a mammal suffering from cancer and in need of treatment comprising administering an effective amount of a compound of Claim 1 in combination with conventional radiation therapy.
34. A method for treating a mammal suffering from cystic fibrosis and in need of treatment comprising administering an effective amount of a compound of Claim 1.
CA002290509A 1997-07-01 1998-06-24 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors Abandoned CA2290509A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5143397P 1997-07-01 1997-07-01
US60/051,433 1997-07-01
PCT/US1998/013105 WO1999001421A1 (en) 1997-07-01 1998-06-24 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors

Publications (1)

Publication Number Publication Date
CA2290509A1 true CA2290509A1 (en) 1999-01-14

Family

ID=21971291

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002290509A Abandoned CA2290509A1 (en) 1997-07-01 1998-06-24 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors

Country Status (17)

Country Link
EP (1) EP0993437B1 (en)
JP (1) JP2002509536A (en)
KR (1) KR20010014360A (en)
AR (1) AR016119A1 (en)
AT (1) ATE344791T1 (en)
AU (1) AU756586C (en)
BR (1) BR9810385A (en)
CA (1) CA2290509A1 (en)
DE (1) DE69836378T2 (en)
ES (1) ES2274572T3 (en)
HR (1) HRP980369A2 (en)
NZ (1) NZ501277A (en)
PE (1) PE98099A1 (en)
TW (1) TWI221831B (en)
UY (1) UY25075A1 (en)
WO (1) WO1999001421A1 (en)
ZA (1) ZA985726B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
WO2011106298A1 (en) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
US11078540B2 (en) 2010-03-09 2021-08-03 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506798B1 (en) 1997-07-01 2003-01-14 Warner-Lambert Company 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
US6846799B1 (en) 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US7354894B2 (en) 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
TR200101704T2 (en) * 1998-12-15 2001-11-21 Warner-Lambert Company Use of a MEK inhibitor to prevent transplant rejection
AU2203800A (en) * 1999-01-07 2000-07-24 Warner-Lambert Company Antiviral method using mek inhibitors
GEP20032999B (en) * 1999-01-13 2003-06-25 Warner Lambert Co 1-Heterocycle Substituted Diarylamines
CA2348236A1 (en) * 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
WO2000050398A2 (en) * 1999-02-24 2000-08-31 F. Hoffmann-La Roche Ag Phenyl- and pyridinyl derivatives as neurokinin 1 antagonists
GB9910579D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910580D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
DK1202724T3 (en) * 1999-07-16 2004-01-26 Warner Lambert Co Method of Treating Chronic Pain Using Mech Inhibitors
EP1202732A2 (en) * 1999-07-16 2002-05-08 Warner-Lambert Company Llc Method for treating chronic pain using mek inhibitors
KR20020012315A (en) * 1999-07-16 2002-02-15 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Method for treating chronic pain using mek inhibitors
AU2001234671B2 (en) 2000-01-31 2006-05-18 Genaera Corporation Mucin synthesis inhibitors
US7345051B2 (en) 2000-01-31 2008-03-18 Genaera Corporation Mucin synthesis inhibitors
GB0002740D0 (en) * 2000-02-07 2000-03-29 Novartis Ag Organic compounds
AU2001247372A1 (en) * 2000-03-15 2001-09-24 Warner Lambert Company 5-amide substituted diarylamines as mex inhibitors
US7001905B2 (en) 2000-03-15 2006-02-21 Warner-Lambert Company Substituted diarylamines as MEK inhibitors
DE10017480A1 (en) * 2000-04-07 2001-10-11 Transmit Technologietransfer Use of substances that act as MEK inhibitors for the manufacture of a medicament against DNA and RNA viruses
US6964982B2 (en) 2000-04-20 2005-11-15 Neurotech Co., Ltd. Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system
WO2002006213A2 (en) 2000-07-19 2002-01-24 Warner-Lambert Company Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
KR20030059115A (en) * 2000-08-25 2003-07-07 워너-램버트 캄파니 엘엘씨 Process for making n-aryl-anthranilic acids and their derivatives
AU2002210714A1 (en) 2000-11-02 2002-06-11 Astrazeneca Ab Substituted quinolines as antitumor agents
AU2001295791A1 (en) 2000-11-02 2002-05-15 Astrazeneca Ab 4-substituted quinolines as antitumor agents
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
DOP2003000556A (en) 2002-01-23 2003-10-31 Warner Lambert Co ESTERES HYDROXAMATE ACID N- (4-PHENYL-REPLACED) -ANTRANILICO.
BR0307060A (en) 2002-01-23 2004-10-26 Warner Lambert Co n- (phenyl-4-substituted) -anthanilic acid hydroxamate esters
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
TWI343377B (en) 2002-03-13 2011-06-11 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
JP4113957B2 (en) 2002-06-19 2008-07-09 アムコア ファーマ， インコーポレイテッド Tetrafluorobenzyl derivative and pharmaceutical composition for prevention and treatment of acute and degenerative cranial nervous system diseases containing the same
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
JP2006513154A (en) * 2002-10-21 2006-04-20 ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and / or cortical neuron activity modulators
WO2005000818A1 (en) 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
BRPI0415710A (en) 2003-10-21 2006-12-19 Warner Lambert Co polymorphic forms of n - [(r) -2,3-dihydroxypropoxy] -3,4-difluoro-2- (2-fluoro-4-yl dophenylamino) benzamide
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
NZ547481A (en) 2003-11-19 2009-12-24 Array Biopharma Inc Heterocyclic inhibitors of mek and methods of use thereof
US20050130954A1 (en) 2003-11-21 2005-06-16 Mitchell Ian S. AKT protein kinase inhibitors
SE0401969D0 (en) * 2004-08-02 2004-08-02 Astrazeneca Ab Piperidine derivatives
AR051248A1 (en) * 2004-10-20 2007-01-03 Applied Research Systems DERIVATIVES OF 3-ARILAMINO PIRIDINA
JP2008520615A (en) * 2004-11-24 2008-06-19 ラボラトワール セローノ ソシエテ アノニム Novel 4-arylaminopyridone derivatives as MEK inhibitors for treating hyperproliferative disorders
ATE443063T1 (en) * 2004-12-01 2009-10-15 Merck Serono Sa A1,2,4ÜTRIAZOLOÄ4,3-AÜPYRIDINE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
DK1860098T3 (en) 2005-03-16 2012-12-17 Toyama Chemical Co Ltd NEW ANTHRANIC ACID DERIVATIVE OR SALTS THEREOF
CN102898364A (en) 2005-05-18 2013-01-30 阵列生物制药公司 Heterocyclic inhibitors of MEK and methods of use thereof
WO2006126846A1 (en) * 2005-05-25 2006-11-30 Choongwae Pharma Corporation Process of preparation of substituted tetrafluorobenzylaniline compound and its pharmaceutically approved salts
AU2013203939B2 (en) * 2005-10-07 2015-08-13 Exelixis, Inc. Azetidines as MEK inhibitors for the treatment of proliferative diseases
CN103524392B (en) * 2005-10-07 2018-06-01 埃克塞利希斯股份有限公司 As for treating the azetidine of the MEK inhibitor of proliferative disease
AU2015255183C1 (en) * 2005-10-07 2017-10-05 Exelixis, Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
AU2012261703B2 (en) * 2005-10-07 2015-08-13 Exelixis, Inc. Azetidines as MEK inhibitors for the treatment of proliferative diseases
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
ATE532789T1 (en) 2006-07-06 2011-11-15 Array Biopharma Inc DIHYDROTHIENOPYRIMIDINES AS ACT PROTEIN KINASE INHIBITORS
WO2008006032A1 (en) 2006-07-06 2008-01-10 Array Biopharma Inc. Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
CN101511842B (en) 2006-07-06 2012-10-31 阵列生物制药公司 Dihydrofuro pyrimidines as AKT protein kinase inhibitors
CA2658725A1 (en) * 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
NZ577047A (en) 2006-10-23 2011-02-25 Takeda Pharmaceutical Mapk/erk kinase inhibitors
ES2703723T3 (en) * 2006-12-14 2019-03-12 Exelixis Inc Methods for using MEK inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
SI2173723T1 (en) 2007-07-05 2011-12-30 Array Biopharma Inc Pyrimidyl cyclopentanes as akt protein kinase inhibitors
US8618097B2 (en) 2007-07-05 2013-12-31 Array Biopharma, Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
EP2203411B1 (en) 2007-09-20 2016-01-06 Ramot at Tel-Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
WO2009037705A2 (en) * 2007-09-20 2009-03-26 Ramot At Tel Aviv University Ltd. Esters of n-phenylanthranilic acid for use in the treatment of cancer and inflammation
KR100852962B1 (en) 2007-11-12 2008-08-20 주식회사 뉴로테크 2-hydroxy-5-phenylalkylaminobenzoic acid derivatives and salts thereof
EP2240455B1 (en) 2008-01-09 2012-12-26 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
JP5346345B2 (en) 2008-01-09 2013-11-20 アレイ バイオファーマ、インコーポレイテッド Hydroxylated pyrimidylcyclopentanes as AKT protein kinase inhibitors
GB0813403D0 (en) * 2008-07-22 2008-08-27 Lectus Therapeutics Ltd Potassium ion channel modulators & uses thereof
SI2307376T1 (en) 2008-08-04 2016-02-29 Merck Patent Gmbh Novel phenylamino isonicotinamide compounds
EP2346818B1 (en) 2008-11-10 2012-12-05 Bayer Intellectual Property GmbH Substituted sulphonamido phenoxybenzamides
WO2011047796A1 (en) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted halophenoxybenzamide derivatives
EP2491016A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
EP2491015A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
CA2816188A1 (en) 2010-10-29 2012-05-03 Marion Hitchcock Substituted phenoxypyridines
KR20140022053A (en) 2011-04-01 2014-02-21 제넨테크, 인크. Combinations of akt and mek inhibitor compounds, and methods of use
ES2620644T3 (en) 2011-04-01 2017-06-29 Genentech, Inc. Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use
CN103204822B (en) 2012-01-17 2014-12-03 上海科州药物研发有限公司 Benzoxazole compounds as protein kinase inhibitors, and preparation method and application thereof
CN102617383A (en) * 2012-03-20 2012-08-01 横店集团家园化工有限公司 Salfaprodil crystal forms, preparation methods, and sterile powder containing salfaprodil crystals
HK1206733A1 (en) * 2012-05-30 2016-01-15 Merck Patent Gmbh Solid state forms of n-((s)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide
HRP20180670T1 (en) * 2012-10-12 2018-07-13 Exelixis Inc. NEW PROCEDURE FOR OBTAINING COMPOUNDS FOR THE USE OF CANCER TREATMENT
EP3043790B1 (en) * 2013-09-11 2021-05-26 The Administrators of the Tulane Educational Fund Novel anthranilic amides and the use thereof
AU2015206603B9 (en) 2014-01-14 2019-07-18 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms
US20170248603A1 (en) 2014-10-06 2017-08-31 Dana-Farber Cancer Institute, Inc. Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response
MA41866A (en) 2015-03-31 2018-02-06 Massachusetts Gen Hospital SELF-ASSEMBLING MOLECULES FOR TARGETED DRUG DELIVERY
MA55141A (en) 2018-11-20 2021-09-29 Nflection Therapeutics Inc CYANOARYL-ANILINE COMPOUNDS FOR THE TREATMENT OF SKIN CONDITIONS
US12378240B2 (en) 2018-11-20 2025-08-05 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
JP7546297B2 (en) 2018-11-20 2024-09-06 エヌフレクション セラピューティクス インコーポレイテッド Thienyl-aniline compounds for the treatment of skin disorders - Patents.com
CA3120351A1 (en) * 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
IL312977A (en) 2021-11-23 2024-07-01 Nflection Therapeutics Inc Formulations of PYRROLOPYRIDINE-ANILINE COMPOUNDS
TW202342018A (en) 2022-03-04 2023-11-01 美商奇奈特生物製藥公司 Inhibitors of mek kinase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2077249A (en) * 1934-06-06 1937-04-13 Winthrop Chem Co Inc Basically substituted acridine compounds
US5525625A (en) * 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
WO1998037881A1 (en) * 1997-02-28 1998-09-03 Warner Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
US9084781B2 (en) 2008-12-10 2015-07-21 Novartis Ag MEK mutations conferring resistance to MEK inhibitors
WO2011106298A1 (en) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
US8637246B2 (en) 2010-02-25 2014-01-28 Dana-Farber Cancer Institute, Inc. BRAF mutations conferring resistance to BRAF inhibitors
US9279144B2 (en) 2010-02-25 2016-03-08 Dana-Farber Cancer Institute, Inc. Screening method for BRAF inhibitors
EP3028699A1 (en) 2010-02-25 2016-06-08 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
US11078540B2 (en) 2010-03-09 2021-08-03 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
US12522872B2 (en) 2010-03-09 2026-01-13 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy

Also Published As

Publication number Publication date
BR9810385A (en) 2000-09-05
DE69836378D1 (en) 2006-12-21
WO1999001421A1 (en) 1999-01-14
PE98099A1 (en) 1999-11-05
AU756586C (en) 2004-01-29
JP2002509536A (en) 2002-03-26
TWI221831B (en) 2004-10-11
EP0993437B1 (en) 2006-11-08
ES2274572T3 (en) 2007-05-16
ZA985726B (en) 1999-01-27
UY25075A1 (en) 1998-12-01
AR016119A1 (en) 2001-06-20
AU756586B2 (en) 2003-01-16
HRP980369A2 (en) 1999-04-30
AU8262698A (en) 1999-01-25
KR20010014360A (en) 2001-02-26
DE69836378T2 (en) 2007-10-11
ATE344791T1 (en) 2006-11-15
NZ501277A (en) 2002-12-20
EP0993437A1 (en) 2000-04-19

Similar Documents

Publication Publication Date Title
AU756586C (en) 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
US6310060B1 (en) 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
US6251943B1 (en) Method of treating or preventing septic shock by administering a MEK inhibitor
AU757046B2 (en) 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
US6821963B2 (en) 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
AU776788C (en) Treatment of arthritis with MEK inhibitors
CA2350234A1 (en) Treatment of asthma with mek inhibitors
ZA200104000B (en) Antiviral method using MEK inhibitors.
OA11733A (en) Combination chemotherapy.
MXPA99010556A (en) 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors
MXPA01005476A (en) Combination chemotherapy
MXPA99010649A (en) 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued